Participated · Series A · Dec 2025

Syneron Bio develops macrocyclic peptide therapeutics using its proprietary, high-throughput Synova™ discovery platform. The company's pipeline is diversified across oncology, autoimmune, metabolic, and rare disease indications. Syneron Bio plans to use the Series B proceeds to further evolve and scale its intelligence-driven Synova™ platform and to accelerate progression of multiple core programs into clinical development. The financing, which strengthened the company's cash position, includes participation from global life-science funds, sovereign wealth, strategic corporates and existing shareholders. Syneron Bio highlights improving platform efficiency and success rates as central to its future discovery and development efforts. The company is headquartered in Beijing.

Led · Series B · Sep 2025

YolTech Therapeutics, founded in 2021 and based in Shanghai, develops next-generation in vivo gene-editing therapies designed as one-time treatments. Its integrated platform includes proprietary CRISPR nucleases (YolCas), base editors (YolBE), and a lipid nanoparticle delivery system (Yol-LNPs) for tissue-specific editing. The company has advanced four clinical-stage programs addressing ATTR, familial hypercholesterolemia (HeFH), primary hyperoxaluria type 1 (PH1), and β-thalassemia/sickle cell disease (TDT/SCD), and its lead program YOLT-201 entered Phase I/IIa in China in 2024. Its base-editing therapy YOLT-101 received IND clearance in both China and the United States. YolTech operates a cGMP-compliant manufacturing facility supporting clinical supply through Phase III and early commercial scale-up to ensure consistency and scalability. The company intends to use financing proceeds to advance its clinical programs and support global strategic execution. 尧唐生物 is a global leader in in‑vivo gene editing and base editing that owns foundational patents for CRISPR/Cas and single‑base deaminase tools. The company maintains three proprietary technology platforms—Cas enzymes, base editors, and lipid nanoparticle (LNP) delivery—with independent IP and core patent protection for global implementation. It has assembled international experts in gene‑editing tool discovery, mRNA‑LNP process development, and CMC to accelerate mRNA‑LNP‑mediated in‑vivo gene‑editing therapeutics and clinical translation. The lead program, YOLT‑201, has completed toxicology and pharmacology studies and shown preliminary safety and efficacy in large‑animal studies, delivering best‑in‑class single‑dose in‑vivo editing efficiency. The company has submitted an IND for YOLT‑201 to China’s NMPA and aims to open a registration clinical trial for an mRNA‑LNP delivered in‑vivo gene‑editing therapy. Financially,尧唐生物 has raised nearly RMB 300 million across its A‑series and recently closed an A+ round of over RMB 100 million to accelerate clinical development and global pipeline expansion.

Led · Series C · May 2023

Cullgen is a privately held clinical-stage biopharmaceutical company applying its proprietary uSMITE™ (ubiquitin-mediated, small molecule-induced target elimination) platform to develop first-in-class new chemical entities. The company focuses on targeted protein degradation to expand drug design beyond functional site inhibition and to target historically “undruggable” proteins. Cullgen has generated multiple highly potent, selective, and bioavailable targeted protein degrader compounds that utilize proprietary novel E3 ligands. Its internal pipeline targets oncology and other diseases. The company said the new financing will support development of its technology platform and internal pipeline of targeted protein degraders. Cullgen is identified with offices/operations in San Diego and Shanghai in the announcement. Cullgen develops small-molecule therapeutics using its proprietary uSMITE™ ubiquitin-mediated targeted protein degradation platform. The company is advancing an internal pipeline of targeted protein degraders for oncology and other diseases and emphasizes discovery of novel E3 ligands. Cullgen plans to file an IND later this year for its most advanced program, CG001419, a TRK protein degrader, and intends to use new capital to move programs into human clinical studies. The company says its uSMITE™ approach enables elimination of previously “undruggable” proteins and aims to be more cost effective than traditional drug discovery. Cullgen operates out of San Diego and Shanghai and is privately held. Cullgen develops targeted protein degraders using its proprietary uSMITE™ (ubiquitin mediated small molecule induced target elimination) platform. The company focuses research programs on novel treatments for cancer, inflammatory, and autoimmune diseases. Cullgen has identified several pre-clinical assets that it is advancing toward the clinic. It is also working to discover novel E3 ligands to incorporate into degrader complexes. Over the past year the company assembled a board of scientific advisors, established a senior management team, and built a state-of-the-art laboratory facility. The lab is run by more than 40 employees. The company intends to use its platform and assets to progress programs into clinical development. Cullgen is building a drug discovery platform based on advanced ubiquitin-mediated protein degradation technology that enables selective degradation of disease-causing proteins, including targets previously considered undruggable. The platform draws on Dr. Yue Xiong’s foundational work since 1998 identifying catalytic and regulatory components and assembly mechanisms of cullin-RING E3 ubiquitin ligases. Cullgen’s founders, including Dr. Xiong and Dr. Jian Jin, have developed multiple new chemical entities (NCEs) against cancer targets and have filed multiple patent applications. Initial discovery programs will focus on oncology with planned expansion into inflammatory and autoimmune diseases. The company is incorporated in Delaware and will initiate research operations in the United States, Japan, and China. Cullgen has established a scientific advisory board and a board of directors that includes executives from its lead investor, GNIG.

Led · Series A · Nov 2022

Rgenta Therapeutics is developing a pipeline of oral small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. The company’s proprietary platform mines large genomics datasets to identify targetable RNA processing events and design small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. Led by CEO Simon Xi, Rgenta is advancing multiple lead programs discovered via this platform. The company plans to use its new capital to speed development of lead programs, enhance target discovery capabilities, and extend platform functionality. The financing is intended to support advancement of a pipeline of RNA-targeting programs across a range of disease indications. No operating metrics were disclosed in the article. Rgenta Therapeutics is a US-based therapeutics company. The company announced an $18 million seed extension round. The extension was backed by Lilly Asia Ventures, which the article describes as China-headquartered. The article does not provide details on Rgenta’s products, pipeline, revenue, users, valuation, or use of proceeds. No other investors, prior rounds, or founding year were mentioned in the coverage. Further operational or financial details were not disclosed. Based in Cambridge, Mass., Rgenta Therapeutics is developing oral, small-molecule RNA-targeting medicines with an initial focus on oncology and neurological disorders. Its proprietary platform mines large genomics datasets to identify targetable RNA processing events and design small-molecule glues that modulate interactions among the spliceosome, regulatory proteins, and RNAs. The company says its discovery engine can rapidly screen for drug-like small molecules to regulate protein production or alter protein function against historically undruggable targets. Rgenta plans to advance its lead RNA-targeting programs into preclinical studies and expand its portfolio to pursue high-value RNA targets across therapeutic areas. The company launched with a $20 million seed investment co-led by Boehringer Ingelheim Venture Fund and Matrix Partners China, with Kaitai Capital and Legend Star Fund participating. Rgenta has assembled a team of small-molecule drug developers and a scientific advisory board including Dr. Zhiping Weng, Dr. Phillip Zamore, Dr. Charles DeLisi, and Dr. Friedrich Metzger.

Led · Equity · Jun 2022

NuProbe Global is a genomics and molecular diagnostics company with sites in Houston, TX, Shanghai, and Suzhou. The company develops molecular diagnostic technologies that improve the sensitivity of sequencing mutations and copy number variations by over 10-fold. NuProbe is led by CEO Yingshuang Chai and co-founder David Zhang, who is also CEO of NuProbe USA. The company raised $50M in funding to support its growth. Proceeds will be used to expand commercial operations, accelerate IVD product clinical studies and regulatory submissions, and develop new genomics and molecular diagnostics technologies. Since its last fundraising in 2021, NuProbe has engaged in research collaborations with several multinational companies and clinical collaborations with over 400 hospitals. NuProbe develops molecular diagnostic technologies and ultrasensitive NGS panels that it says improve detection of sequencing mutations and copy number variations by over 10-fold. The company has signed partnership and licensing deals with Illumina, Qiagen, Oxford Nanopore and the Wego Group, and has begun partnering with pharma companies for clinical research using its Augury™ custom NGS panels. In China’s reproductive health market NuProbe has built collaborations with most top hospitals and is described as a leader in infertility testing. Led by co-founder and CEO Yingshuang Chai, the team includes co-founder and Head of Innovation David Zhang and a scientific advisory board featuring David Walt and George Church. NuProbe operates out of Houston (USA), Shanghai and Suzhou (China). The company plans to expand its commercial teams in the US and China, develop new NGS products, and pursue regulatory approval in China for its clinical products. NuProbe develops toehold probe–based molecular diagnostics technology licensed from Harvard’s Wyss Institute and Rice University to enable highly sensitive, multiplexed detection of disease signatures in cell-free DNA. Its core product focus is on ultra-sensitive, non-invasive blood tests for early cancer detection, infectious disease, and other genomics applications, with platforms intended for cancer, NIPT, and infectious-disease diagnostics. In pre-clinical work the technology improved qPCR and NGS mutation detection sensitivity by 10–100×, achieving limits of detection down to 0.01% and demonstrating multiplexing of 10–100 reactions capable of detecting hundreds of mutations. The proprietary assays are compatible with common PCR and sequencing workflows, which the company says supports clinical applicability. NuProbe plans to use new funding to grow staff in its Cambridge, Mass. and China offices and to continue technology development, clinical trials, and commercialization efforts. Financially, the company recently completed an $11 million Series A to support these development and go-to-market activities.